Gethin R. Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gethin R. Ellis has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Justin S W Taylor
1 shared publicationJustin S. W. Taylor
Department of Medicine, Royal Glamorgan Hospital, Llantrisant, United Kingdom
1 shared publication
Latest Publications
- 1 January 2002
- Vol. 2 (6)
Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure.
- 1 January 2002
- Vol. 2 (6)
Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure.
- 1 January 2002
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 2 (6) , 389-399
Racial Differences in Responses to Drug Treatment
Chronic heart failure (CHF) is a common disease with high associated morbidity and mortality, and the outcome appears to be worse in black compared with white patients. There is currently no clear consensus for basing the pharmacological treatment of CHF on racial differences. Most studies that have investigated the potential effects of racial differences on pharmacological responses in heart failure have been based on African Americans and white participants. Using these data, this review will discuss the current understanding of the effects of racial differences in response to pharmacotherapy in heart failure, possible mechanisms for these observed differences, and how this may impact on patient management.
- 1 January 2002
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 2 (6) , 389-399
Racial Differences in Responses to Drug Treatment
Chronic heart failure (CHF) is a common disease with high associated morbidity and mortality, and the outcome appears to be worse in black compared with white patients. There is currently no clear consensus for basing the pharmacological treatment of CHF on racial differences. Most studies that have investigated the potential effects of racial differences on pharmacological responses in heart failure have been based on African Americans and white participants. Using these data, this review will discuss the current understanding of the effects of racial differences in response to pharmacotherapy in heart failure, possible mechanisms for these observed differences, and how this may impact on patient management.